Selecta has launched a unique set of equipment
Selecta (RUS) has commissioned unique equipment for the production of synthetic vaccine particles
Vitaly Shustikov, Skolkovo Press Center
Selecta (RUS) (Khimki), a resident of the biomedical technologies cluster of the Skolkovo Foundation and the RUSNANO portfolio company, has completed the installation and commissioned a unique set of equipment for the production of synthetic vaccine particles (SVP™) for the development and further clinical studies of a new class of immunomodulating nanopreparations. The equipment was developed by special order of Selecta (RUS) based on the company's unique prototypes and standard components. Dmitry Ovchinnikov, General Director of Selecta (RUS), Candidate of Biological Sciences:
"The successful launch of this equipment is an important stage in the implementation of our plans. The installation will accelerate the development of innovative products and help to quickly confirm the importance of using synthetic vaccine particles in one of the most promising approaches in cancer treatment – immuno-oncology."
The installed equipment makes it possible to synthesize batches of vaccine particles both for research activities in the laboratory and for the industrial production of medicines. In the latter case, the installation does not require any modifications and is placed on a licensed pharmaceutical production. The implementation of the system will make it easy to scale the SVP production process for various Selecta (RUS) projects, including platforms for the treatment of certain cancers associated with the human papillomavirus (cervical, neck and head cancers). This platform activates immune system cells, known as cytotoxic T-lymphocytes (CTL), against cancer cells transformed by the human papillomavirus.
The project for the treatment of these types of oncological diseases received the support of the Skolkovo Foundation in the form of a grant of 150 million rubles to continue the development of a therapeutic vaccine and its withdrawal from preclinical to an early stage of clinical research.
Kristina Khodova, Head of the Oncology/Immunology Direction of the Biomedical Technologies Cluster of the Skolkovo Foundation, Candidate of Medical Sciences:
"New technologies for the prevention and treatment of oncological diseases are one of the priorities of the biomedical cluster of the Skolkovo Foundation, therefore the immunotherapeutic developments of Selecta (RUS) constitute an important part of our ecosystem. The laboratory equipment allowed us to bring the successful implementation of the company's projects one step closer."
Earlier this year, Selecta Biosciences, Inc. announced the start of cooperation with Genethone – the SVP™ platform will be used in the company's gene therapy to protect viral carriers from the action of antibodies and other undesirable immune reactions.
In September 2015, Selecta Biosciences, Inc. completed a $38 million Series E funding round. The funds will be used to develop several candidates for the role of antigen-specific immunotherapy products based on the SVP™ platform. The efforts of the company's employees will be focused on the clinical trial program of the leading candidate product SEL-212, which is being developed as the first non-immunogenic biotherapy for the treatment of gout.
Portal "Eternal youth" http://vechnayamolodost.ru
27.10.2015